Immutep secures third U.S. patent for eftilagimod alpha

Immutep announced the grant of a new patent entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent Office. This United States patent was filed as a second divisional application and follows the grant of the United States parent patent and first divisional patent announced in December 2020 and March 2021, respectively. The claims of the new patent build on the protection provided by the two previously granted patents, and are directed to methods of treating cancer by administering Immutep’s lead active immunotherapy candidate eftilagimod alpha and a PD-1 pathway inhibitor, specifically BMS-936559, durvalumab, atezolizumab or avelumab. The expiry date of the patent is 15 November 2036. A continuation application and a further divisional application have been filed to pursue other embodiments of the invention.